Somerville, MA, United States of America

Matthew Iadanza

This inventor holds 2 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Aileron Therapeutics, Inc.. Active years: 2015-2016.

USPTO Granted Patents = 2 

% Patents Active = 50.0


 

Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 54(Granted Patents)


Company Filing History:


Years Active: 2015-2016

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Matthew Iadanza: Innovator in Polypeptide Composition

Introduction

Matthew Iadanza is a notable inventor based in Somerville, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of purified polypeptide compositions. With a total of 2 patents to his name, Iadanza's work is paving the way for advancements in therapeutic applications.

Latest Patents

Iadanza's latest patents focus on methods for preparing purified peptidomimetic macrocycles. The present invention relates to these purified macrocycles and provides methods for their preparation and use, particularly in therapeutic applications. This innovative approach has the potential to enhance the efficacy of various treatments.

Career Highlights

Matthew Iadanza is currently employed at Aileron Therapeutics, Inc., where he continues to push the boundaries of research in his field. His work at Aileron Therapeutics is instrumental in developing new therapeutic strategies that leverage his expertise in polypeptide compositions.

Collaborations

Iadanza collaborates with esteemed colleagues, including Huw M Nash and Christopher Leitheiser. These partnerships foster a dynamic research environment that encourages innovation and the sharing of ideas.

Conclusion

In summary, Matthew Iadanza is a dedicated inventor whose work in polypeptide compositions is making a significant impact in the field of biochemistry. His contributions are essential for the advancement of therapeutic applications, and his ongoing research promises to yield further innovations in the future.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…